RT Journal Article
SR Electronic
T1 COVID-19 Susceptibility and Severity Risks in a Survey of Over 500,000 People
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.08.20209593
DO 10.1101/2020.10.08.20209593
A1 Knight, Spencer C.
A1 McCurdy, Shannon R.
A1 Rhead, Brooke
A1 Coignet, Marie V.
A1 Park, Danny S.
A1 Roberts, Genevieve H.L.
A1 Berkowitz, Nathan D.
A1 Zhang, Miao
A1 Turissini, David
A1 Delgado, Karen
A1 Pavlovic, Milos
A1 Team, AncestryDNA Science
A1 Baltzell, Asher K. Haug
A1 Guturu, Harendra
A1 Rand, Kristin A.
A1 Girshick, Ahna R.
A1 Hong, Eurie L.
A1 Ball, Catherine A.
YR 2020
UL http://medrxiv.org/content/early/2020/10/16/2020.10.08.20209593.abstract
AB The growing toll of the COVID-19 pandemic has heightened the urgency of identifying individuals most at risk of infection and severe outcomes, underscoring the need to assess susceptibility and severity patterns in large datasets.1 The AncestryDNA COVID-19 Study collected self-reported survey data on symptoms, outcomes, risk factors, and exposures for over 563,000 adult individuals in the U.S., including over 4,700 COVID-19 cases as measured by a self-reported positive nasal swab test. We observed significant associations between several risk factors and COVID-19 susceptibility and severity outcomes. Many of the susceptibility associations were accounted for by differences in known exposures; a notable exception was elevated susceptibility odds for males after adjusting for known exposures and age. We also leveraged the dataset to build risk models to robustly predict individualized COVID-19 susceptibility (area under the curve [AUC]=0.84) and severity outcomes including hospitalization and life-threatening critical illness amongst COVID-19 cases (AUC=0.87 and 0.90, respectively). The results highlight the value of self-reported epidemiological data at scale to provide public health insights into the evolving COVID-19 pandemic.Competing Interest StatementThe authors declare competing financial interests: authors affiliated with AncestryDNA may have equity in Ancestry.Funding StatementAll work was supported and funded by AncestryDNAAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data for this research project were from subjects who have provided informed consent to participate in AncestryDNA's Human Diversity Project, as reviewed and approved by our external institutional review board, Advarra (formerly Quorum). All data were de-identified prior to use.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe plan to make a dataset available to qualified scientists through the European Genome-phenome Archive (EGA). The EGA dataset includes the risk factors and outcomes studied here, for a different set of individuals.